SCHEMBL6209793

SCHEMBL6209793

C=C(COc1ccccc1)CC1(O)CCCN(C(=O)OC(C)(C)C)C1c1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR1H2 P55055 4/20 0.40
▸ RXRA P19793 3/20 0.40
▸ NR1H3 Q13133 3/20 0.40
▸ KLK7 P49862 1/20 0.39
▸ HCRTR2 O43614 1/20 0.38
▸ ALDH1A1 P00352 4/20 0.38
▸ KMT2A Q03164 3/20 0.38
▸ L3MBTL1 Q9Y468 2/20 0.38
▸ KDM1A O60341 2/20 0.38
▸ MEN1 O00255 2/20 0.38
▸ LMNA P02545 2/20 0.38
▸ TSHR P16473 1/20 0.38
▸ ABCB1 P08183 1/20 0.37
▸ RIPK1 Q13546 1/20 0.37
▸ MAPT P10636 3/20 0.36
▸ RAB9A P51151 2/20 0.36
▸ SMN1; SMN2 Q16637 2/20 0.36
▸ NPC1 O15118 1/20 0.36
▸ TP53 P04637 1/20 0.36
▸ CPT1A P50416 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5781644 1.00 NR1H2 (0.40) NR1H2RXRANR1H3KLK7HCRTR2
SCHEMBL8057876 0.85 L3MBTL1 (0.39) ALDH1A1KMT2AL3MBTL1MEN1LMNA
SCHEMBL8147798 0.85 NR1H2 (0.41) NR1H2RXRANR1H3KLK7HCRTR2
SCHEMBL9024216 0.77 NR1H2 (0.47) NR1H2RXRANR1H3KLK7HCRTR2
SCHEMBL8156778 0.76 HCRTR2 (0.40) NR1H2RXRANR1H3KLK7HCRTR2
SCHEMBL8156782 0.76 HCRTR2 (0.40) NR1H2RXRANR1H3KLK7HCRTR2
SCHEMBL8156779 0.76 HCRTR2 (0.40) NR1H2RXRANR1H3KLK7HCRTR2
SCHEMBL8148106 0.72 ABCB1 (0.38) NR1H2RXRANR1H3KLK7HCRTR2
SCHEMBL8148159 0.72 ABCB1 (0.38) NR1H2RXRANR1H3KLK7HCRTR2
SCHEMBL8148104 0.72 ABCB1 (0.38) NR1H2RXRANR1H3KLK7HCRTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0942733-B1 USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING COGNITIVE DISORDERS MERCK SHARP & DOHME (GB) 2005-04-27 — — EP disclosed
EP-0941093-B1 USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING MAJOR DEPRESSIVE DISORDERS WITH ANXIETY MERCK SHARP & DOHME (GB) 2005-02-09 — — EP disclosed
EP-0941092-B1 USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING MAJOR DEPRESSIVE DISORDERS MERCK SHARP & DOHME (GB) 2004-12-29 — — EP disclosed
EP-0942732-B1 USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING MOVEMENT DISORDERS MERCK SHARP & DOHME (GB) 2004-11-17 — — EP disclosed
US-6071927-A Spiro-piperidine derivatives and their use as therapeutic agents MERCK SHARP & DOHME LTD. (GB) 2000-06-06 — — US disclosed
US-6060469-A Spiro-piperidine derivatives and their use as tachykinin antagonists MERCK SHARP & DOHME LTD. (GB) 2000-05-09 — — US disclosed
US-5952315-A TREATING PHYSIOLOGICAL DISORDERS, DISORDERS OF THE CENTRAL NERVOUS SYSTEM SUCH AS ANXIETY, DEPRESSION AND PSYCHOSIS WITH AN ANTIDEPRESSANT MERCK SHARP & DOHME LTD. (GB) 1999-09-14 — — US disclosed
WO-1999007373-A1 USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING MANIA MERCK SHARP & DOHME LIMITED (GB) 1999-02-18 — — WO disclosed
Send feedback